

REMARKS

Claims 32, 44, 45 are canceled without prejudice or disclaimer. Claim 59 is amended. Therefore, claims 1, 2, 4, 5, 7-20, 22, 23, 59 and 61 are pending.

The Office Action makes a restriction requirement between the following groups:

Group I – claims 1, 2, 4, 5, 7-20, 22 and 23

Group II – claims 32, 44, 45, 59 and 61.

The restriction requirement is traversed in part. Applicants submit that claims 59 and 61 should be examined with Group I since they share unity of invention.

Applicants hereby elect the invention of Group I and their previous election of the species: galactose epimerase as the enzyme, UDP-galactose as the inhibitory compound, and galactose as the precursor. Applicants agree that only claims 1, 2, 4, 5, 7-10, 15-20, 22 and 23 read on the elected species. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Date: May 8, 2003